Tirzepatide-induced gastrointestinal manifestations: A systematic review and meta-analysis, Cureus (2023) The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists, Diabetes, Obesity, and Metabolism (2020) What is the incidence of pancreatitis associated with Zepbound (tirzepatide)?, Eli Lilly website (2024) Constipation and impaction, Harvard Health (2023) Pancreatitis, Johns Hopkins Medicine (2025) Gallstones and gallbladder disease, Mount Sinai Zepbound label, Food and Drug Administration (2025) Gingers nutritional implication on gastrointestinal health, Clinical Nutrition Open Science (2025) Review article: The physiologic effects and safety of peppermint oil and its efficacy in irritable bowel syndrome and other functional disorders, Alimentary Pharmacology and Therapeutics (2018) Efficacy and safety of peppermint oil in a randomized double-blind trial of patients with irritable bowel syndrome, Gastroenterology (2020) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice

The initial dose is gradually increased to achieve better glycemic control: Starting dose : 0.25 mg once weekly for the first 4 weeks (not effective for glycemic control)
In addition, a study conducted on live organisms indicated that ghrelin treatment effectively inhibited tumor progression in the colon of mice with inflammation-related colon cancer caused by azoxymethane/DSS (106)
We aim to elucidate how GLP-1 participates in the early stages of taste perception, the molecular and neural mechanisms underlying this process, and its broader implications for understanding the pathophysiology of obesity and the therapeutic effects of GLP-1RAs
Editors Picks What if doctors could use GLP-1 drugs like Ozempic to treat Alzheimer's disease